Body Composition and Serum Prostate-Specific Antigen: Review and Findings from Flint Men's Health Study

Urology

Volumn 71, Issue 4, 2008, Pages 554-560

  Beebe Dimmer, Jennifer L ^a   Faerber, Gary J ^b   Morgenstern, Hal ^c   Werny, David ^b   Wojno, Kirk ^b   Halstead Nussloch, Bronwen ^c   Cooney, Kathleen A ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; BODY COMPOSITION; CANCER SCREENING; DISEASE ASSOCIATION; HUMAN; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW;

ADULT; AFRICAN AMERICANS; AGED; BODY COMPOSITION; BODY WEIGHTS AND MEASURES; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 41149084887     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.049     Document Type: Review

References (45)

1. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
2. Hernandez J., and Thompson I.M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101 (2004) 894-904
3. Thompson I., Leach R.J., Pollock B.H., et al. Prostate cancer and prostate-specific antigen: the more we know, the less we understand. J Natl Cancer Inst 95 (2003) 1027-1028
4. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
5. Ankerst D.P., and Thompson I.M. Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Arch Ital Urol Androl 78 (2006) 125-129
6. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 4 Pt 1 (2004) 1297-1301
7. Freedland S.J., Terris M.K., Presti Jr. J.C., et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol 172 (2004) 520-524
8. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
9. Amling C.L., Kane C.J., Riffenburgh R.H., et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 58 (2001) 723-728
10. Gong Z., Neuhouser M.L., Goodman P.J., et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15 (2006) 1977-1983
11. Rodriguez C., Freedland S.J., Deka A., et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 16 (2007) 63-69
12. Strom S.S., Wang X., Pettaway C.A., et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res 11 19 Pt 1 (2005) 6889-6894
13. Wright M.E., Chang S.C., Schatzkin A., et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109 (2007) 675-684
14. Freedland S.J., and Platz E.A. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 29 (2007) 88-97
15. Baillargeon J., Pollock B.H., Kristal A.R., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103 (2005) 1092-1095
16. Cooney K.A., Strawderman M.S., Wojno K.J., et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 57 (2001) 91-96
17. Heeringa S.G., Alcser K.H., Doerr K., et al. Potential selection bias in a community-based study of PSA levels in African-American men. J Clin Epidemiol 54 (2001) 142-148
18. Lean M.E., Han T.S., and Morrison C.E. Waist circumference as a measure for indicating need for weight management. BMJ 311 (1995) 158-161
19. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in theUnited States, 1999-2004. JAMA 295 (2006) 1549-1555
20. National Center for Health Statistics, 1999. http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99.htm Accessed June 20, 2007
21. Colditz G.A. Economic costs of obesity and inactivity. Med Sci Sports Exerc 31 11 suppl (1999) S663-S667
22. Manson J.E., Skerrett P.J., Greenland P., et al. The escalating pandemics of obesity and sedentary lifestyle: a call to action for clinicians. Arch Intern Med 164 (2004) 249-258
23. Davi G., Guagnano M.T., Ciabattoni G., et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288 (2002) 2008-2014
24. Harvie M., Hooper L., and Howell A.H. Central obesity and breast cancer risk: a systematic review. Obes Rev 4 (2003) 157-173
25. Kaaks R., Lukanova A., and Kurzer M.S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11 (2002) 1531-1543
26. Lukanova A., Lundin E., Zeleniuch-Jacquotte A., et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150 (2004) 161-171
27. Sandhu M.S., Gibson J.M., Heald A.H., et al. Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev 13 (2004) 166-170
28. Schottenfeld D., and Beebe-Dimmer J.L. Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. Ann Rev Pub Health 26 (2005) 37-60
29. Amling C.L., Riffenburgh R.H., Sun L., et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 22 (2004) 439-445
30. Freedland S.J., Aronson W.J., Kane C.J., et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22 (2004) 446-453
31. Rodriguez C., Patel A.V., Calle E.E., et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10 (2001) 345-353
32. Calle E.E., Rodriguez C., Walker-Thurmond K., et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625-1638
33. Buschemeyer III W.C., and Freedland S.J. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52 (2007) 331-343
34. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
35. Schottenfeld D., and Colditz G.A. Prostate cancer screening practices and cancer control research (United States). Cancer Causes Control 13 (2002) 1-5
36. Bosch J.L., Hop W.C., Bangma C.H., et al. Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Prostate 27 (1995) 241-249
37. Smith D.S., Carvalhal G.F., Mager D.E., et al. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 160 (1998) 1734-1738
38. Thompson I.M., Leach R., Troyer D., et al. Relationship of body mass index and prostate specific antigen in a population-based study. Urol Oncol 22 (2004) 127-131
39. Kristal A.R., Chi C., Tangen C.M., et al. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 106 (2006) 320-328
40. Fowke J.H., Signorello L.B., Chang S.S., et al. Effects of obesity and height on prostate specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer 107 (2006) 2361-2367
41. Barqawi A.B., Golden B.K., O'Donnell C., et al. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65 (2005) 708-712
42. Werny D.M., Thompson T., Saraiya M., et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16 (2007) 70-76
43. Ku J.H., Kim M.E., Lee N.K., et al. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Urology 61 (2003) 132-136
44. Ochiai A., Fritsche H.A., and Babaian R.J. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 66 (2005) 819-823
45. Fowke J.H., Motley S.S., Cookson M.S., et al. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 10 (2007) 137-142